Alan Lau
Impact in
- Oncology top 0.5%
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
- Cancer Research top 2%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 29
- PARP inhibition in cancer therapy 19
- Cancer-related Molecular Pathways 6
-
- DNA Repair Mechanisms 29
- Cancer therapeutics and mechanisms 7
- CRISPR and Genetic Engineering 6
- Cell death mechanisms and regulation 2
- Co-authors
- Mark J. O’Connor (20 shared papers)Timothy Anthony Yap (2 shared papers)Johann Sebastian De Bono (1 shared paper)Stan B. Kaye (1 shared paper)Andrew N.J. Tutt (1 shared paper)Jan H.M. Schellens (1 shared paper)Helen Swaisland (1 shared paper)Peter C.C. Fong (1 shared paper)
- Journals
- Molecular Cancer Therapeutics (5 papers)Clinical Cancer Research (5 papers)Blood (3 papers)Cancer Research (3 papers)Journal of Medicinal Chemistry (3 papers)
- Partner nations
- United KingdomUnited StatesNetherlands
In The Last Decade
Alan Lau
49 papers receiving 8.0k citations
Alan Lau's Hit Papers
Peers
Comparison fields: 5 of 115
- Oncology 5.2k
- Cancer Research 1.0k
- Molecular Biology 5.0k
- Reproductive Medicine 477
- Genetics 1.1k
Countries citing papers authored by Alan Lau
This map shows the geographic impact of Alan Lau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Lau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Lau more than expected).
Fields of papers citing papers by Alan Lau
This network shows the impact of papers produced by Alan Lau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Lau. The network helps show where Alan Lau may publish in the future.
Co-authors
The 25 scholars most cited alongside Alan Lau, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 50 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers Hit paper breakdown → | 2009 | 3057 |
| 2 | High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Hit paper breakdown → | 2008 | 821 |
| 3 | 2008 | 519 | |
| 4 | 2012 | 432 | |
| 5 | 2008 | 288 | |
| 6 | 2015 | 236 | |
| 7 | 2005 | 220 | |
| 8 | 2015 | 208 | |
| 9 | 2013 | 171 | |
| 10 | 2020 | 146 | |
| 11 | 2012 | 140 | |
| 12 | 2013 | 133 | |
| 13 | 2005 | 125 | |
| 14 | 2017 | 122 | |
| 15 | 2016 | 112 | |
| 16 | 2009 | 100 | |
| 17 | 2021 | 91 | |
| 18 | 2018 | 89 | |
| 19 | 2018 | 77 | |
| 20 | 2015 | 75 |
About Alan Lau
Alan Lau is a scholar working on Oncology, Molecular Biology, Genetics, Cancer Research and Genetics, having authored 50 papers that have together received 8.1k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (29 papers), PARP inhibition in cancer therapy (19 papers), Cancer therapeutics and mechanisms (7 papers), CRISPR and Genetic Engineering (6 papers), Cancer-related Molecular Pathways (6 papers), Chronic Lymphocytic Leukemia Research (3 papers), Cancer Genomics and Diagnostics (2 papers) and Cell death mechanisms and regulation (2 papers). The work is most often cited by research in Oncology (5.2k citations), Cancer Research (1.0k citations), Molecular Biology (5.0k citations), Reproductive Medicine (477 citations) and Genetics (1.1k citations). Alan Lau has collaborated with scholars based in United Kingdom, United States and Netherlands. Frequent co-authors include Mark J. O’Connor, Timothy Anthony Yap, Johann Sebastian De Bono, Stan B. Kaye, Andrew N.J. Tutt, Jan H.M. Schellens, Helen Swaisland, Peter C.C. Fong, Alan Ashworth and Marja Mergui‐Roelvink. Their work appears in journals such as Molecular Cancer Therapeutics, Clinical Cancer Research, Blood, Cancer Research and Journal of Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.